Pacific Biosciences Of California (PACB) Cash from Financing Activities (2010 - 2026)

Pacific Biosciences Of California's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 26.65% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $2.9 million, a 106.11% increase from a year earlier, with the FY2025 full-year figure at $3.4 million, up 107.97% from the prior year.
• Cash from Financing Activities eased to $1.4 million in Q1 2026 per PACB's latest filing, from $1.5 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $196.0 million in Q1 2023 and bottomed at -$81.6 million in Q4 2023.
• The 5-year median for Cash from Financing Activities is $819000.0 (2022), against an average of $5.4 million.
• Biggest YoY gain for Cash from Financing Activities was 3658.18% in 2023; the steepest drop was 10063.61% in 2023.
• Year by year, Cash from Financing Activities stood at $819000.0 in 2022, then tumbled by 10063.61% to -$81.6 million in 2023, then surged by 38.48% to -$50.2 million in 2024, then surged by 102.93% to $1.5 million in 2025, then dropped by 2.18% to $1.4 million in 2026.
• Per Business Quant, the three latest PACB Cash from Financing Activities figures stand at $1.4 million (Q1 2026), $1.5 million (Q3 2025), and $2.0 million (Q1 2025).